Status:
UNKNOWN
CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Lead Sponsor:
Korea University Anam Hospital
Collaborating Sponsors:
Korea University
Conditions:
Breast Neoplasms
Arthralgia
Eligibility:
FEMALE
18-80 years
Brief Summary
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and t...
Eligibility Criteria
Inclusion
- The patient must sign the informed consent.
- The patient must sign the informed consent of genetic screening test.
- The patient must be between 18 years old and 80 years old who can make a decision independently.
- The patient must be post-menopause status.
- The patient should be the stage 1,2 or 3 of the breast cancer.
- The test result of the estrogen receptor or progesterone receptor is positive, so the patient should be taking the medication of AI (Aromatase Inhibitor).
Exclusion
- The patient is pre-menopause status.
- The test result of serum FSH level is below 30mU/ml.
- The test result of the hormone receptor(ER \& PR) is negative or unknown.
- Patient's breast cancer stage is 4 which has systemic metastatics.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00973505
Start Date
March 1 2009
End Date
September 1 2010
Last Update
September 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Anam Hopital
Seoul, South Korea, 136-705